What changed
$PFE — Develops and manufactures pharmaceutical medicines and vaccines.
🎯 Q1 FY26 | Rev $14B | EPS $0.75 vs $0.72 🟢
💡 Consensus expects a steady recovery driven by pipeline and cost cuts, but the market is ignoring that Q1 revenue growth ex-COVID products was only 7% operational, below the 10%+ needed to justify the current valuation. The EPS beat was small (3.9%) and driven by cost controls, not top-line acceleration.
🏢 Business Quality: 7/10 | Valuation: fair
📉 Reward/Risk: Upside 12% to $29.50 (10x FY26 EPS of $2.96) vs downside 10% to $23.70 (8x FY26 EPS). Ratio: 1.2:1, not compelling for a 3-month horizon.
🔮 Catalyst: Next earnings (late July 2026): Q2 EPS and revenue vs consensus $0.85 and $16.1B. Key metric: ex-COVID revenue growth rate. Failure signal: <5% operational growth ex-COVID or guidance cut.
💰 Entry: Current price $26.30 is near the lower end of 52-week range ($24-$30).
Also in play: $GIS $K $CPB $CAG $SJM $ADM